Stanley Druckenmiller Arcellx, Inc. Transaction History
Duquesne Family Office LLC
- $2.95 Billion
- Q3 2024
A detailed history of Stanley Druckenmiller (Duquesne Family Office LLC) transactions in Arcellx, Inc. stock. As of the latest transaction made, Duquesne Family Office LLC holds 74,100 shares of ACLX stock, worth $5.6 Million. This represents 0.21% of its overall portfolio holdings.
Number of Shares
74,100
Previous 74,100
-0.0%
Holding current value
$5.6 Million
Previous $4.09 Million
51.3%
% of portfolio
0.21%
Previous 0.14%
Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
204Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$302 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$294 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$283 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$266 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$186 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.31B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...